ABSTRACT
INTRODUCTION
Major structural malformations occur in 2-3% of newborns and account for nearly 25% of perinatal deaths [1] [2] [3] , although the true proportion could in fact be much higher, as structural abnormalities are frequently associated with fetal loss. It is noteworthy that the majority of structural anomalies occur in fetuses without a family history of congenital malformation 2 , which has made prenatal genetic counseling challenging, leading clinicians to advocate ultrasonographic screening of all pregnant women for the prenatal detection of major birth defects 4 . Fetuses with structural anomalies have a greater incidence of aneuploidy, other chromosomal rearrangements and monogenic disorders. Conventional karyotyping is a classic method for detecting chromosomal rearrangements, with a diagnostic rate ranging from 5.4% to 15.5% 5, 6 . The development of array-based molecular cytogenetic techniques, such as chromosomal microarray analysis (CMA), has increased by up to 10% the detection rate of small genomic deletions and duplications that are not observed routinely on standard karyotyping of structurally malformed fetuses 7, 8 .
In the majority of fetuses with structural malformations, the underlying cause of the anomaly remains unknown. As a significant development in next-generation sequencing, whole exome sequencing (WES) has proven to be a powerful tool for evaluating postnatal patients, achieving an average molecular diagnostic rate of 25% 9 . This technology is also being applied gradually to prenatal diagnosis 10 . Carss et al. 11 recently presented WES results from 30 fetuses with structural abnormalities that were cytogenetically normal, in which pathogenic variants were identified in 10% of cases. Yang et al. 12 diagnosed neurological findings in 6 of 11 fetuses from terminated pregnancies, demonstrating improved diagnostic yield using WES. Drury et al. 13 reported WES results from 24 fetuses with either isolated increased nuchal translucency or nuchal translucency in combination with other structural abnormalities, in which five cases with pathogenic variants were identified. However, the use of WES as a prenatal diagnostic tool has been evaluated only in studies with a small sample size, such as in studies of fetuses with single ultrasound findings or studies of non-consecutive samples of fetuses. Using WES to evaluate a larger sample size would provide not only a more accurate diagnostic rate, but also additional information, such as on how to categorize subgroups based on phenotypic severity, which could aid in the identification of pathogenic variants.
METHODS

Participant recruitment and sample collection
This study was approved by the institutional review board of the ethics committee in our unit. All parents agreed to participate in the study and provided signed informed consent. From January 2011 to December 2015, a total of 3988 pregnant women were referred to our Prenatal Diagnostic Center, due to the detection of fetal structural malformations on prenatal ultrasound examination and/or magnetic resonance imaging. Ultrasound examinations and/or magnetic resonance imaging were performed at our center to confirm the diagnosis. The anomalies included structural malformation, nuchal translucency thickness ≥ 3.5 mm and cystic hygroma. The anomalies did not include isolated sonographic soft markers such as choroid plexus cysts, echogenic foci in the heart or bowel, thickened nuchal fold, absent nasal bone, single umbilical artery or persistent right umbilical vein. The fetal samples were collected using chorionic villus sampling, amniocentesis and cordocentesis according to gestational age at the time of invasive prenatal testing.
Karyotype analysis
Samples from all 3988 cases were analyzed using quantitative fluorescence polymerase chain reaction (QF-PCR) for rapid prenatal diagnosis of common aneuploidy (13, 18, 21 , X or Y). This was followed by standard G-banded karyotyping to diagnose overall chromosomal abnormalities according to standard laboratory procedures.
Chromosomal microarray analysis
For fetal samples with a normal karyotype, we investigated submicroscopic genomic imbalances using whole-genome high-resolution microarray analysis with cytoScan HD arrays and cytoScan 750 K arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocols and as described previously 8 . Detected copy number variants (CNVs) were evaluated systematically for clinical significance by comparing them with values in the scientific literature and in the following publicly available databases: database of genomic variants (DGV, http://dgv.tcag.ca/dgv/app/ home), DECIPHER database (http://decipher.sanger.ac .uk/), the International Standards for Cytogenomic Arrays (ISCA, https://www.iscaconsortium.org/), Online Mendelian Inheritance in Man (OMIM, http://www .omim.org) and UCSC (http://genome.ucsc.edu/). According to the guideline, the CNVs identified using CMA were classified as pathogenic, variants of uncertain significance (VOUS) or benign. A total of 1710 fetal cases were subjected to CMA. All de novo CNVs revealed by CMA were confirmed by a second method, such as fluorescence in-situ hybridization (FISH) or quantitative real-time PCR (qPCR). CMA was also performed on DNA samples isolated from parental whole blood to assist in interpreting CNVs and to determine patterns of inheritance.
Whole exome sequencing
WES was provided as a purely research-based adjunct to standard prenatal diagnosis by QF-PCR, karyotyping and chromosomal microarray analysis. Genomic DNA samples were extracted from chorionic villi, amniocytes, cord blood or parental blood using a Qiagen DNA Blood Midi/Mini kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's protocol.
DNA libraries were prepared using a NEXTflex™ Rapid DNA Sequencing Kit (5144-02) (Bioo Scientific, Austin, TX, USA) according to the manufacturer's protocol. The libraries were tested for enrichment by qPCR, and size distribution and concentration were determined using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). A HiSeq2500 sequencer was used for sample sequencing according to the manufacturer's protocol (version 3; Illumina, Inc., San Diego, CA, USA). Paired-end sequencing was performed for each sample.
Raw image files were processed using Bcl To Fastq (Illumina) for base calling and generating raw data. Low-quality sequencing reads were filtered out using a quality score ≥ 20 (Q20). The reads were aligned to the NCBI human reference genome (hg19/GRCh37) using the Burrows-Wheeler Aligner tool. BAM files were subjected to single nucleotide polymorphism (SNP) analysis, duplication marking, indel realignment and recalibration using SAMtools and Pindel. 
Data filtering
Data from fetus-mother-father trio samples were analyzed first. In the initial round of analysis, variants in fetuses were selected in accordance with the following criteria: (1) sequencing depth ≥ 4 and mutation frequency ≥ 0.1; (2) MAF < 0.01 when referring to dbSNP build 142, the 1000 Genomes Project and the ExAC Browser; (3) variants located in coding regions or exon-intron junctions; (4) deleterious protein or splicing predictions; and (5) variants in a gene responsible for an OMIM disease/phenotype. In the second round of analysis, variants were further selected according to the following disease inheritance models: (1) genes associated with autosomal recessive disease, defined as variants in homozygous or compound heterozygous fetuses with parents who are heterozygous carriers; (2) genes associated with autosomal dominant disease, defined as de novo variants in fetuses (i.e. neither of the parents has the same variants) or variants inherited from either of the parents for non-lethal or late-onset diseases; (3) genes associated with X-linked recessive disease, characterized by hemizygous male fetuses with heterozygous mothers; and (4) genes associated with X-linked dominant disease, characterized by de novo variants in fetuses or variants in fetuses that were inherited from either of the parents in the case of non-lethal or late-onset disease. All the selected variants were then classified as pathogenic, likely pathogenic, VOUS, likely benign or benign according to the American College of Medical Genetics and Genomics (ACMG) guidelines 14, 15 . Variants from fetal proband only were analyzed according to the same five criteria used to evaluate the fetus-mother-father trio data. As no parental data were available, the variants filtered out in the trio data in the second round and that were finally classified as VOUS, likely benign or benign were used as an internal database to filter additional variants from proband fetuses. Further clinical classification was performed for the remaining variants according to ACMG guidelines. A flowchart describing the data analysis method is presented in Figure 1 .
Sanger sequencing confirmation
Sanger sequencing confirmation was performed for all variants suspected of being clinically significant.
RESULTS
Karyotype analysis
A flowchart of genetic analysis progression is presented in Figure 2 . Of the total cohort, 3978 were singleton pregnancies and 10 were twin pregnancies in which one of the fetuses with a structural abnormality was recruited according to the criteria of the study. The median maternal age was 31 (range 20-45) years, and the fetuses were assessed at median gestational age of 27 (range 17-36) weeks. Adequate samples with successful karyotyping results were obtained from 3949 fetuses (723 from chorionic villus sampling, 1318 from amniocentesis and 1908 from cordocentesis). Overall, 18.2% (720/3949) of fetuses had an abnormal karyotype. Of these, 70.7% showed aneuploidy, 21% had a chromosomal rearrangement and 8.3% had mixed numerical and structural aberrations. Trisomy 21 was the most common abnormality, being detected in 177 (4.5%) samples. This was followed by trisomy 18, detected in 122 (3.1%) samples, and trisomy 13, detected in 51 (1.3%) samples. Karyotyping results are summarized in Table 1 and detection rates in Table 2 .
Chromosomal microarray analysis
CMA was successfully performed for 1680 fetuses, of which 396 belonged to the multiple malformation group and 1284 to the single malformation group. CMA identified CNVs with likely clinical significance in 138 fetuses, yielding an 8.2% (138/1680) overall detection rate. Among these, the detection rate of pathogenic CNVs in the multiple malformation group was 12.6% (50/396), and in the single malformation group was 6.9% (88/1284) ( Table 2 ). The CNVs identified as likely pathogenic and pathogenic in our cohort are summarized in Table S1 . 22q11.21 deletion associated with velocardiofacial and DiGeorge syndrome was the most frequent CNV found, comprising 12.3% (17/138) of the total pathogenic CNVs found by CMA. This was followed by the chromosomal 1p36.33∼p36.22 deletion and the 17q12 deletion.
Whole exome sequencing
Samples from 196 fetuses with normal karyotyping and CMA results and 49 pairs of parents were subjected to WES (297 individuals in total, including three families with father-mother-proband-fetus samples). It is worth mentioning that all fetal cases that received WES were associated with structural abnormalities including malformation of the central nervous system, cardiovascular system, skeletal system, digestive system and urinary system and craniofacial malformation and multiple malformations, but did not include nuchal translucency thickness ≥ 3.5 mm, cystic hygroma and other ultrasound soft markers. The detection rates of structural malformations by WES are summarized in Table 2 . The mean depth of coverage for the coding regions targeted with the WES was 102×. A mean of 99.56% of bases in the targeted coding regions were covered by at least 10 reads.
One group included fetus-mother-father samples (n = 49), while the other included proband-only samples (n = 147). The CNVs in all samples were evaluated by high-resolution microarray analysis with a minimum resolution of up to 25-50 kb, and therefore we did not pay special attention to CNVs during our WES data analysis. We first identified 817 potential single nucleotide variants (SNVs) and small indels (64 in the fetus-mother-father trio group and 753 in the proband group). We ultimately validated 95 variants with potential clinical significance,
Failed culture (n =39) Figure 2 Flowchart of genetic analysis progression in cohort of fetuses with structural malformations. CMA, chromosomal microarray analysis; CNVs, copy number variants; VOUS, variants of unknown significance; WES, whole exome sequencing. with a mean of 0.48 per exome. Of these, 52 variants were identified in the fetus-mother-father trio group and 43 in the fetal proband-only group, yielding mean values of 0.94 (range 0-2) per trio exome and 0.34 (range 0-5) per fetal exome. The variants were distributed in 59 fetal samples and generated a total positive detection rate of 30.1% (59/196); however, 12 of them were not considered to be directly related to the malformation phenotypes observed and were therefore classified as incidental findings. Thus, the true positive rate for the detection of genetic variants underlying the abnormal fetal phenotypes was 24% (47/196), while the incidental detection rate was 6.1% (12/196) . The pathogenic variants likely to be responsible for the abnormalities observed on the fetal ultrasound examination are summarized in Table 3 . The variants that were incidentally identified and potentially associated with risk for a condition unrelated to malformed phenotype are summarized in Table S2 . After removing incidental findings that were not related to fetal phenotype, the overall molecular diagnosis rate was 26.5% (13/49) for the fetus-mother-father samples and 23.1% (34/147) for the proband-only samples. We then categorized the fetal samples into subgroups based on malformation phenotype observed and assessed the pathogenic detection rate for each subgroup. In the single-malformation subgroup, a definitive diagnosis was made in 35/157 (22.3%) cases; in the multiple-malformation subgroup, a molecular diagnosis was made in 12/39 (30.8%) cases. A comparison of the molecular diagnosis rate for each malformation type was also performed, yielding the following results: multiple malformations (30.8%; 12/39), skeletal system malformation (30%; 3/10), urogenital system malformation (23.1%; 6/26), dysmorphic facial features (23.5%; 4/17), central nervous system malformation (23.1%; 15/65), cardiovascular system malformation (20.6%; 7/34), digestive system malformation (0; 0/5) ( Table 3) .
Seventy-five (78.9%) of the 95 validated variants were de novo mutations in coding or splicing sequences and followed an autosomal dominant inheritance pattern; this included 45 missense, 14 frame-shift, 10 nonsense and six splice-site mutations. Ten cases (10/59; 16.9%) were found to share variants with potential significance in overlapping genes. Another 20 variants (21.1%) were identified as functional hemizygous, homozygous or compound heterozygous mutations in accordance with their recessive and X-linked patterns of inheritance. Of these variants, eight were missense, five were nonsense, three were frameshift and four were in splice sites. There were still 25 variants distributed in the fetal samples that could not be classified due to the criteria not being met and to being defined as VOUS, yielding an overall VOUS detection rate of 12.8% (25/196) . Of these, 22 variants were identified in the fetal proband group (15%; 22/147) and three in the fetus-mother-father group (6.1%; 3/49). The VOUS observed in the fetuses are summarized in Table S3 .
We also attempted to detect the carriers of recessive hereditary disease. To accomplish this, we first identified single pathogenic allele variants in genes corresponding to recessive genetic disease in 23/196 (11.7%) fetuses. Similarly, we also screened for recessive carriers in the parental samples and found 8/49 (16.3%) couples simultaneously carrying a pathogenic mutant allele of the same gene. Because the chance of inheritance of an allele is 25%, the real risk for a pregnancy being affected by a recessive hereditary disease in these cases was 4.1%. There was a significant difference in the recessive carrier yield between the fetal and parental group (11.7% vs 4.1%, P < 0.01).
DISCUSSION
This study represents one of the largest cohorts of fetuses with structural malformations to undergo genomic analysis with karyotyping, CMA and WES. Cytogenetic karyotyping revealed abnormal karyotype in 18.2% of fetuses. The incidence of chromosomal aberrations was slightly lower than that found in other prenatal studies 16, 17 ; however, the present study was conducted on a larger scale. The general detection rate of 8.2% by CMA in our study was slightly higher than the 6% mean reported in the largest scale study conducted to date 18 . Nevertheless, a pure whole-genome high-resolution SNP array was used in our study and there is an expectation that denser arrays, such as this one, will detect a greater proportion of clinically significant CNVs 19 . Our results suggested that, to achieve a successful prenatal diagnosis of structural abnormalities, QF-PCR should be used to rapidly identify common aneuploidies, followed by CMA to detect genomic imbalances. This combination offers both cost-effectiveness and fast turnaround.
There are over 4000 phenotypes in OMIM with a known genetic basis 20 . Therefore, after applying WES 9, 12, 21 , but higher than those reported in other small prenatal studies 11, 13 . The lower diagnostic rate in our study might be due to the fact that prenatal phenotypic evaluation is limited and genotype-phenotype assessments are extremely difficult 13 . This enhanced diagnostic yield has the potential to improve the clinical management of pregnancies and better inform family planning efforts. The turnaround time of WES for individual cases was approximately 3 weeks and the results were likely to have been obtained prior to the end of pregnancy and used for pregnancy or perinatal management.
WES achieved a molecular diagnosis rate of 26.5% (13/49) in fetus-mother-father samples and 23.1% (34/147) in proband-only samples. This indicates that WES achieves greater sensitivity when using trios compared with proband-only samples. This is likely because performing WES on trios increases the sensitivity for detecting de novo and compound heterozygous variants. In turn, de novo variants can be used potentially to identify novel disease-causing genes 22 . In the present study, 78.9% of the variants were de novo null mutations, indicating that prenatal carrier screening is insufficient and that fetuses themselves must be evaluated. In addition, VOUS were significantly higher in the proband-only group (15%; 22/147) than in the trios (6.1%; 3/49). The reason for this difference is that the parental data could help to verify the origin of the variants (de novo or inherited) identified in the fetus, which is critical evidence for clinical classification. Thus, the use of WES to evaluate fetus-mother-father samples is ideal for prenatal diagnosis based on our results.
WES achieved molecular diagnostic rates of 22.3% (35/157) in the single malformation group and 30.8% (12/39) in the multiple malformations group. This difference in detection rate is in accordance with the biological nature of disease, with more severe phenotypes being more likely to correlate with genomic instability 23 . The fetuses that are referred to our center display a broad range of phenotypic malformations associated potentially with genetic disorders.
A large percentage of our cases (20/59; 33.9%) were found to have more than one genetic variant potentially responsible for the observed phenotype. Because the structural abnormalities in the majority of cases were identified by routine ultrasound examination performed at 22-24 gestational weeks and the fetal phenotypes were non-specific, the multiple diagnoses made highlight the efficiency of prenatal WES. There has been much discussion on how to interpret incidental findings on WES [24] [25] [26] [27] . The 6.1% (12/196 ) rate of incidental findings in our study again raises this question. It is expected that a higher rate of incidental findings would occur in prenatal cases compared with postnatal patients (5%) 12 because phenotypic assessments are often inadequate during prenatal diagnosis. Current ACMG guidelines recommend the reporting of incidental results that are associated with diseases that can be managed well with medical intervention, specifically pathogenic variants identified in 59 genes in postnatal patients 25, 27 . However, clinically handling incidental findings on prenatal diagnosis will present greater ethical challenges. Relevant consensuses and guidelines should be established, more in-depth information should be provided during prenatal counseling and parents should have the option of receiving information that is unrelated to fetal phenotype.
There are some limitations to our study. Due to the retrospective nature of the investigation, no conclusion on the impact on clinical care can be made. In the future, with the turnaround time getting faster and the cost reducing, couples with fetuses with congenital malformation might be provided with WES in order to make a definitive prenatal diagnosis as early on in pregnancy as possible. This is important for informing parental choice and, where appropriate, guiding delivery plans, treatment on delivery or even in-utero therapy 28 . Only a minority of the cohort that underwent WES was assessed as trios; this limits the clinical utility of information and detection rate, especially if the genetic sources of variation are deficient. There is little doubt that the application of WES can increase the diagnostic yield but, for it to be clinically useful, data interpretation guidelines should specify parental samples available for parallel testing. Moreover, many fetal cases were excluded due to insufficient DNA, i.e. not all underwent CMA and WES, which might bias the results, and it may not be possible to represent the real distribution of genes and variants in prenatal cases with congenital structural abnormalities. In particular, the majority of fetal cases were at late gestation. Further improving the handling of fresh amniotic samples could reduce this bias in the future. Issues of ethics and consent should also be borne in mind when implementing WES into clinical care 29 . In conclusion, the present study demonstrates that WES is a promising method with which to identify genetic variants that cause structural fetal abnormalities, but that yield negative results on karyotyping and CMA. This enhanced diagnostic yield has the potential to improve the clinical management of pregnancies and inform better the reproductive decisions of affected families. However, the interpretation of fetal WES data can be challenging, due to the constraints of short time frames and incomplete phenotype information. 
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Summary of pathogenic and likely pathogenic copy number variants revealed by prenatal chromosomal microarray analysis in 1680 pregnancies with structurally malformed fetus Table S2 Summary of incidental findings on prenatal whole exome sequencing in 196 structurally malformed fetuses Table S3 Summary of variants of uncertain significance identified by prenatal whole exome sequencing in 196 structurally malformed fetuses in (a) proband-only samples and in (b) fetus-mother-father trio samples
